Arvinas (ARVN) Competitors $7.58 +0.18 (+2.43%) Closing price 04:00 PM EasternExtended Trading$7.34 -0.24 (-3.10%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARVN vs. AAPG, NAMS, MTSR, ARQT, DNLI, RXRX, HRMY, BEAM, GLPG, and CNTAShould you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Ascentage Pharma Group International (AAPG), NewAmsterdam Pharma (NAMS), Metsera (MTSR), Arcutis Biotherapeutics (ARQT), Denali Therapeutics (DNLI), Recursion Pharmaceuticals (RXRX), Harmony Biosciences (HRMY), Beam Therapeutics (BEAM), Galapagos (GLPG), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical products" industry. Arvinas vs. Ascentage Pharma Group International NewAmsterdam Pharma Metsera Arcutis Biotherapeutics Denali Therapeutics Recursion Pharmaceuticals Harmony Biosciences Beam Therapeutics Galapagos Centessa Pharmaceuticals Arvinas (NASDAQ:ARVN) and Ascentage Pharma Group International (NASDAQ:AAPG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations. Is ARVN or AAPG more profitable? Ascentage Pharma Group International has a net margin of 0.00% compared to Arvinas' net margin of -75.51%. Ascentage Pharma Group International's return on equity of 0.00% beat Arvinas' return on equity.Company Net Margins Return on Equity Return on Assets Arvinas-75.51% -33.75% -16.75% Ascentage Pharma Group International N/A N/A N/A Do institutionals and insiders believe in ARVN or AAPG? 95.2% of Arvinas shares are held by institutional investors. 5.2% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media prefer ARVN or AAPG? In the previous week, Arvinas had 10 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 13 mentions for Arvinas and 3 mentions for Ascentage Pharma Group International. Ascentage Pharma Group International's average media sentiment score of 1.39 beat Arvinas' score of 0.61 indicating that Ascentage Pharma Group International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Ascentage Pharma Group International 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor ARVN or AAPG? Arvinas received 196 more outperform votes than Ascentage Pharma Group International when rated by MarketBeat users. However, 100.00% of users gave Ascentage Pharma Group International an outperform vote while only 66.78% of users gave Arvinas an outperform vote. CompanyUnderperformOutperformArvinasOutperform Votes19766.78% Underperform Votes9833.22% Ascentage Pharma Group InternationalOutperform Votes1100.00% Underperform VotesNo Votes Do analysts recommend ARVN or AAPG? Arvinas currently has a consensus target price of $34.53, suggesting a potential upside of 355.58%. Given Arvinas' higher probable upside, research analysts plainly believe Arvinas is more favorable than Ascentage Pharma Group International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arvinas 0 Sell rating(s) 5 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.69Ascentage Pharma Group International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, ARVN or AAPG? Ascentage Pharma Group International has higher revenue and earnings than Arvinas. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArvinas$263.40M1.98-$198.90M-$2.77-2.74Ascentage Pharma Group International$980.65M1.73N/AN/AN/A SummaryArvinas and Ascentage Pharma Group International tied by winning 7 of the 14 factors compared between the two stocks. Remove Ads Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARVN vs. The Competition Export to ExcelMetricArvinasPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$521.29M$6.32B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.32%P/E Ratio-2.746.7921.7317.81Price / Sales1.98225.93379.1994.60Price / CashN/A65.6738.1534.64Price / Book0.935.866.464.00Net Income-$198.90M$141.86M$3.20B$247.23M7 Day Performance22.46%8.98%6.54%7.26%1 Month Performance-10.08%-12.65%-8.55%-6.26%1 Year Performance-78.17%-11.99%10.33%-0.18% Arvinas Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARVNArvinas3.7037 of 5 stars$7.58+2.4%$34.53+355.6%-79.6%$521.29M$263.40M-2.74420Short Interest ↓High Trading VolumeAAPGAscentage Pharma Group InternationalN/A$20.10-4.1%N/AN/A$1.75B$980.65M0.00600Gap DownNAMSNewAmsterdam Pharma2.2865 of 5 stars$15.88+0.4%$43.33+172.9%-16.6%$1.74B$45.56M-6.114Short Interest ↑Gap DownHigh Trading VolumeMTSRMetseraN/A$16.45-2.1%$47.00+185.7%N/A$1.73BN/A0.0081ARQTArcutis Biotherapeutics3.0563 of 5 stars$14.26-3.2%$18.80+31.8%+26.9%$1.69B$196.54M-7.97150DNLIDenali Therapeutics4.1325 of 5 stars$11.54-2.1%$37.20+222.5%-27.3%$1.68B$330.53M-4.18430Analyst RevisionRXRXRecursion Pharmaceuticals2.1183 of 5 stars$4.16-1.8%$8.25+98.1%-34.5%$1.67B$58.49M-2.72400News CoverageHRMYHarmony Biosciences4.5903 of 5 stars$28.36-3.1%$53.33+88.1%+0.1%$1.63B$714.73M13.44200Short Interest ↓Positive NewsBEAMBeam Therapeutics2.9697 of 5 stars$15.26-0.1%$49.45+224.1%-34.4%$1.52B$63.52M-8.67510Short Interest ↑High Trading VolumeGLPGGalapagos0.7929 of 5 stars$23.08-2.8%$25.33+9.8%-20.0%$1.52B$275.65M0.001,123News CoveragePositive NewsHigh Trading VolumeCNTACentessa Pharmaceuticals2.8833 of 5 stars$11.31-3.2%$27.71+145.2%+5.5%$1.51B$6.85M-7.39200Gap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies AAPG Competitors NAMS Competitors MTSR Competitors ARQT Competitors DNLI Competitors RXRX Competitors HRMY Competitors BEAM Competitors GLPG Competitors CNTA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARVN) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
